Gastrointestinal Cancers Symposium (ASCO GI) | Conference

Watch-and-Wait Approach a Potential Option for Patients With Rectal Cancer

January 18th 2017

A watch-and-wait approach is emerging as a potential treatment strategy for patients with rectal cancer.

Analysis Shows Link Between Daily Physical Activity and Improved mCRC Outcomes

January 18th 2017

Patients with metastatic colorectal cancer who engaged in daily moderate physical activity demonstrated a reduction in mortality and cancer progression.

Dr. Bekaii-Saab on Benefits Associated With Regorafenib for CRC

February 29th 2016

Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses the benefits patients receive with regorafenib for the treatment of colorectal cancer.

Mismatch Repair-Deficient GI Tumors Respond to Anti—PD-1 Therapy

January 26th 2016

Mismatch repair-deficient gastrointestinal tumors are highly responsive to checkpoint blockade with anti-PD-1 therapy.

PFS in Metastatic Colorectal Cancer Similar with Two Chemo Backbones

January 26th 2016

A potential biomarker to guide chemotherapy for metastatic colorectal cancer failed to stratify patients by progression-free survival or responsiveness to bevacizumab.

Dr. Kunz on the CLARINET Study for GEP-NETs

January 26th 2016

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses tumor response in the CLARINET study, which examined lanreotide depot versus placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Dr. Melis on Avoiding Surgery for Patients With Rectal Cancer

January 26th 2016

Marcovalerio Melis, MD, associate professor, Department of Surgery, NYU Langone Medical Center, discusses a study examining if surgery can be avoided in patients with advanced rectal cancer by using diffusion-weighted magnetic resonance imaging to predict pathologic response.

Three Drugs Marginally Better Than Two in First-Line Metastatic Colorectal Cancer

January 25th 2016

Patients with metastatic colorectal cancer (mCRC) had marginal yet inconsistent improvement in clinical outcomes when treated with a three-drug chemotherapy regimen plus bevacizumab compared with a doublet-bevacizumab regimen.

Neoadjuvant Carboplatin/Paclitaxel Showing Potential in Esophageal Cancer

January 25th 2016

Neoadjuvant treatment with carboplatin and paclitaxel-based chemotherapy produced a 27.9% pathologic complete response rate in patients with resectable esophageal cancer, according to results of the NEOSCOPE trial.

Avelumab Clinically Active in Advanced Gastric/GEJ Cancer

January 23rd 2016

The investigational anti–PD-L1 antibody avelumab demonstrated clinical activity as a second-line and maintenance therapy for patients with unresectable gastric or gastroesophageal junction cancer.

Dr. Shahda on BBI-608 With Gemcitabine and Nab-Paclitaxel in Patients with mPDAC

January 23rd 2016

Safi Shahda, MD, assistant professor of Clinical Medicine, Indiana University School of Medicine, discusses a phase Ib study examining the cancer stem cell pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.

Dr. Hong on High-Dose Hypofractionated Proton Beam Therapy for Liver Cancer

January 23rd 2016

Theodore S. Hong, MD, director, Gastrointestinal Service, Department of Radiation Oncology, discusses high-dose hypofractionated proton beam therapy for unresectable primary liver cancers.

Neoadjuvant Sorafenib Shows Significant Activity in HCC

January 23rd 2016

Nearly a quarter of patients with resectable hepatocellular carcinoma experienced major tumor necrosis of greater than or equal to 50% following preoperative treatment with sorafenib.

Nivolumab Shows Clinical Activity in Gastric Cancer

January 22nd 2016

The PD-1 inhibitor nivolumab (Opdivo) had an overall response rate of 14% with an acceptable safety profile in patients with gastric or gastroesophageal junction cancer.

Pembrolizumab Active in Advanced Esophageal Carcinoma

January 22nd 2016

The PD-1 inhibitor pembrolizumab (Keytruda) elicited encouraging activity with mild adverse events as a treatment for patients with advanced PD-L1–positive esophageal carcinoma.

Dr. Abou-Alfa on Sorafenib Plus Doxorubicin in Patients With HCC

January 22nd 2016

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the CALGB 80802 study, which examined sorafenib versus sorafenib plus doxorubicin in patients with advanced hepatocellular carcinoma in the first-line setting.

Dr. Bekaii-Saab on Sequencing Regorafenib and TAS-102 in CRC

January 22nd 2016

Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses sequencing regorafenib and TAS-102 for the treatment of patients with colorectal cancer.

Nivolumab Active in Heavily Pretreated Esophageal Cancer

January 22nd 2016

The immune checkpoint inhibitor nivolumab demonstrated activity in patients with previously treated esophageal cancer.

Liposomal Irinotecan OS Advantage Maintained in Updated Pancreatic Cancer Data

January 21st 2016

Adding liposomal irinotecan to 5-fluorouracil and leucovorin reduced the risk of death by 25% for patients with metastatic pancreatic cancer following progression on a gemcitabine-based regimen.

Holly Prigerson on Chemotherapy Regimens for Patients With Advanced Gastric Cancer

January 21st 2016

Holly G. Prigerson, PhD, professor of Sociology in Medicine, Irving Sherwood Wright Professor in Geriatrics, Joan and Sanford I. Weill Department of Medicine, director, Center for Research on End of Life Care, Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses chemotherapy regimens for patients with advanced gastric cancer.

NEXT PAGE
PREVIOUS PAGE
x